Aromatase inhibitor-associated musculoskeletal symptoms: incidence and associated factors

Purpose Arthralgia is the most common side effect in breast cancer patients receiving aromatase inhibitor (AI) therapy. Few studies have evaluated the risk factors, onset, and incidence of musculoskeletal pain in these patients. This study identifies the risk factors of AI-related severe arthralgia and their prevalence. Methods All the clinical and pathological records of postmenopausal patients diagnosed with invasive breast cancer using AI at Samsung Medical Center from January 2005 to November 2007 were reviewed. Multivariate logistic regression analyses were performed to evaluate the risk factors of AI-associated musculoskeletal symptoms (AIMSS) and factors associated with AI discontinuance. Results Among 299 patients, 69 patients (23%) experienced musculoskeletal symptoms attributed to AI use. In multivariate logistic regression analysis, no statistically significant outcome was found to confirm the risk factors for the development of AIMSS. Among the 69 patients who experienced AI-associated musculoskeletal symptoms, 29 (39.7%) discontinued AI use. Multivariate logistic regression analyses revealed an association of prior tamoxifen use with discontinuance of AI (P < 0.01; odds ratio, 4.27; 95% confidence interval, 1.74 to 10.50). Conclusion Prior use of tamoxifen is related to discontinuation of AI due to AI-associated severe arthralgia. Special monitoring and proper pain control for these patients should be considered during the treatment period.

• Publication year

  2013

• Venue

  Journal of the Korean Surgical Society

• Publication date

  2013-10-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.4174/jkss.2013.85.5.205PMID 24266010PMCID 3834018
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Abdominal wall defect with large duodenal disruption treated by a free tissue flap with a help of temporary expandable metallic stent

  2013cited by this paper
• Successful hybrid operation of an acute mobile thrombus in the abdominal aorta induced by chemotherapy

  2011cited by this paper
• Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

  2010cited by this paper
• Patterns and risk factors associated with aromatase inhibitor‐related arthralgia among breast cancer survivors

  2009cited by this paper
• Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?

  2009cited by this paper
• Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors

  2008cited by this paper
• Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.

  2008influential reference
• Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.

  2007cited by this paper
• Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

  2007influential reference
• Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer.

  2007influential reference
• Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.

  2006cited by this paper
• Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

  2005cited by this paper
• Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva.

  2001cited by this paper
• Aromatase inhibitors and arthralgia.

  2001cited by this paper
• Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva.

  2001cited by this paper
• Survivors

  1891cited by this paper

• Musculoskeletal symptoms associated with aromatase inhibitors in the treatment of early breast cancer: A scoping review of risk factors and outcomes

  2025cites this paper
• Current and future advances in practice: aromatase inhibitor–induced arthralgia

  2024cites this paper
• Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy

  2022cites this paper
• Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management

  2021cites this paper
• What influences aromatase inhibitor continuation intention among breast cancer survivors?

  2021cites this paper
• Aromatase Inhibitor Musculoskeletal Syndrome

  2021cites this paper
• Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia

  2019cites this paper
• Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia

  2019cites this paper
• Clinical Symptoms and Quality of Life: Insomnia and Muscle/Joint Aches

  2017cites this paper
• Chapter 130 – Sleep and Fatigue in Cancer Patients

  2017cites this paper
• Characterization and pharmacogenetics of hepatic phase I exemestane metabolism

  2017cites this paper
• Determinants of Physical Activity Maintenance in Breast Cancer Survivors After a Community-Based Intervention.

  2016influential citation
• Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.

  2016cites this paper
• Cancer treatments and their side effects are associated with aggravation of insomnia: Results of a longitudinal study

  2015cites this paper
• Musculoskeletal pain and health-related quality of life among breast cancer patients treated with aromatase inhibitors

  2015cites this paper
• Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.

  2014cites this paper
• A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI

  2014cites this paper